BIOCORP Announces Partnership with AARDEX Group to Extend Smart Solutions for Precision Medication Adherence
Regulatory News:
BIOCORP (Paris:ALCOR) (FR0012788065 - ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, today announced an alliance with Belgium-based AARDEX Group, the world leader in medication adherence solutions.
This alliance is to combine BIOCORP’s connected add-on solutions for drug delivery devices with AARDEX’s proprietary Medication Event Monitoring System (MEMS®) and offer a comprehensive solution to patients and healthcare providers to effectively measure and manage medication adherence. The financial terms of the agreement have not been disclosed, however the first initiative will be to integrate BIOCORP’s Injay connected solution for Pre-filled syringes (PFS) to AARDEX’s MEMS Adherence Software (MEMS AS®), to target medicines delivered by PFS with potential applications in the field of Rheumatoid Arthritis, Multiple Sclerosis, Ophthalmology, Psoriasis or Cardiovascular diseases. The roadmap also includes integration with BIOCORP’s other connected devices, to cover further chronic conditions in the field of injectable, respiratory, and beyond.
David Dalla Vecchia, CEO and Financial Lead of AARDEX Group, said: "We are delighted to announce our partnership with BIOCORP. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment. Partnering with BIOCORP - a true pioneer in connected devices - will significantly contribute to that objective and bring together a wealth of knowledge and experience to help meet the needs of today’s clinical trials, patients and healthcare providers.”
Éric Dessertenne, CEO of BIOCORP, concluded: “This collaboration with AARDEX Group brings a strong added value to our products and to our targeted users. Thanks to the integration with MEMS AS, a unique solution that analyzes deeply patient patterns and behaviors, we will go beyond just monitoring treatment adherence, by providing comprehensive and tailored solutions to boost patient’s engagement and effectively manage this issue. AARDEX specific expertise in clinical trials is also a strong asset and will enable us to create relationships with pharma companies right from the development stage of a drug”.
Medication adherence issues are well known by all healthcare stakeholders and its clinical and commercial impact have been quantified and heavily documented for many years now. The World Health Organization has stated that, in developed countries, adherence to long-term therapies in the general population is only around 50%. But this issue is not limited to commercialized drugs and real-life conditions, it also massively affects clinical trials, which impacts assessment of drug efficacy.
ABOUT AARDEX GROUP
AARDEX Group is the world leader in digital solutions to measure and manage medication adherence. Located in Belgium, in Switzerland and in the U.S., AARDEX develops and markets digital solutions for adherence-enhancing strategies in clinical trials, research settings, and professional healthcare systems. AARDEX is the central actor of a complete ecosystem that combines its MEMS® Adherence Software with a wide range of smart packages and devices that measure patient adherence across all routes of drug administration. Our vision is to continuously innovate in data-driven medication adherence solutions to enhance digital therapeutics and patient empowerment.
For more information, visit www.aardexgroup.com
ABOUT BIOCORP
Recognized for its expertise in the development and manufacture of medical devices and delivery systems, BIOCORP has today acquired a leading position in the connected medical device market thanks to Mallya. This intelligent sensor for insulin injection pens allows reliable monitoring of injected doses and thus offers better compliance in the treatment of diabetics. Available for sale from 2020, Mallya spearheads BIOCORP's product portfolio of innovative connected solutions. The company has 54 employees.
BIOCORP is listed on Euronext since July 2015 (FR0012788065 – ALCOR).
For more information, please visit www.biocorpsys.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200930005883/en/
Contact information
FOR MEDIA ENQUIRIES - ON BEHALF OF AARDEX GROUP
Sophie Beattie
sophie@discovery-pr.com
Mobile: + 44 (0) 7494 129 339
BIOCORP CONTACTS
Jacques Gardette
Chairman of the Board
investisseurs@biocorp.fr
Éric Dessertenne
Chief Executive Officer
Sylvaine Dessard
Marketing & Communication Director
rp@biocorp.fr
+ 33 (0)6 88 69 72 85
ULYSSE COMMUNICATION CONTACTS
Bruno ARABIAN
barabian@ulysse-communication.com
+33 (0)6 87 88 46 26
Nicolas DANIELS
ndaniels@ulysse-communication.com
+33 (0)6 63 66 59 22
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SABCS 2025: REVEAL GENOMICS Presents Major Advance in Predicting Brain Metastasis in HER2+ Breast Cancer8.12.2025 17:20:00 EET | Press release
REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company focused on advancing precision oncology through biomarker innovation, announced today the presentation of seven studies at the upcoming San Antonio Breast Cancer Symposium (SABCS) 2025, held December 9–12 in San Antonio, Texas. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208979141/en/ These abstracts showcase the growing clinical utility and innovation of the company’s proprietary RNA platform and underscore REVEAL GENOMICS’ commitment to improving outcomes for individuals with breast cancer. Across all studies, REVEAL GENOMICS and its collaborators analyzed more than 1,300 tumor samples from individuals with HER2-positive, ER-negative, and triple-negative breast cancer—one of the most extensive genomic contributions to SABCS 2025. Seven independent studies validate the performance and clinical impact of REVEAL GENOMICS’ precision oncology platform New HER2
NetApp Advances EMEA & LATAM Presence with Appointment of Willem Hendrickx as Customer Demand for AI Accelerates8.12.2025 17:15:00 EET | Press release
NetApp (NASDAQ: NTAP), the intelligent data infrastructure company, today announced the appointment of Willem Hendrickxas Senior Vice President and General Manager, EMEA & LATAM, effective January 5, 2026. Hendrickxwill lead NetApp’s business strategy, go-to-market execution, and partner engagement across Europe, the Middle East, Africa, and Latin America. Reporting to NetApp President César Cernuda, Hendrickx brings a deep regional knowledge and track record of building high-performing teams, further enabling the acceleration of NetApp’s international footprint by helping global customers navigate the evolving demands of hybrid cloud and AI-driven data infrastructure. Hendrickx holds a Master’s degree in Applied Economics from KU Leuven and is based in Brussels, Belgium. “Willem joins NetApp at a pivotal time as customer demand surges for intelligent, AI-driven, cloud-enabled data infrastructure globally,” said César Cernuda, President, NetApp. “This appointment underscores our commit
MediaKind and Harmonic’s Video Business to Combine, Creating a Leading Streaming-Infrastructure Platform8.12.2025 16:37:00 EET | Press release
MediaKind, a global leader in cloud-based video streaming technology, today announced it has entered into an agreement to acquire the Video Business of Harmonic Inc. (NASDAQ: HLIT) for approximately $145 million. Following a French employee works council consultation process, the parties would immediately execute a purchase agreement, and the transaction would be expected to close in the first half of 2026, subject to customary regulatory approvals and closing conditions. The transaction creates a world-class independent SaaS streaming infrastructure provider by combining two established video technology organizations with complementary strengths in SaaS streaming, appliance platforms, and cloud AV workloads. The combined company will serve a blue-chip customer base, generate more than $100 million in annual recurring revenue (ARR), over $150 million in annual appliance revenue, and, as a business 100% focused on video, create an enhanced foundation for long-term growth. Additionally,
Andersen Consulting Elevates Cybersecurity Offering with the Addition of S-RM8.12.2025 16:30:00 EET | Press release
Andersen Consulting enters into a Collaboration Agreement with S‑RM, a global intelligence and cybersecurity consultancy, strengthening its ability to support global clients with risk resilience, incident response, and strategic advisory. Headquartered in the UK, S-RM delivers integrated services spanning cyber advisory, digital forensics, incident response, corporate intelligence, and pre-transaction due diligence. The firm serves family offices, private equity, Fortune 500, and mid-market clients in industries such as financial services, oil, and healthcare, offering hands-on cybersecurity management and custom risk platforms. With 24/7 incident response and deep investigative expertise, S-RM helps organizations strengthen resilience and make informed decisions in complex environments. “In an era where threats evolve constantly, organizations must be proactive, not reactive,” said Heyrick Bond Gunning, CEO of S‑RM. “Through our collaboration with Andersen Consulting, we will better e
Boomi Named a 2025 Geo and Global AWS Partner Award Finalist8.12.2025 16:00:00 EET | Press release
Boomi™, the leader in AI-driven automation, today announced it is a finalist for a 2025 Geography and Global AWS Partner Award, recognizing leaders around the globe that are playing key roles in helping their customers drive innovation and build solutions on Amazon Web Services (AWS). Boomi is excited to announce it has been named a finalist for Rising Star Partner of the Year (Technology), which honors the top AWS Partner that has seen significant year-over-year growth in their Technology business. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251208700959/en/ Boomi Named a 2025 Geo and Global AWS Partner Award Finalist The Geography and Global AWS Partner Awards recognize a wide range of AWS Partners that have embraced specialization, innovation, and cooperation over the past year. Geo and Global AWS Partner Awards commend partners whose business models continue to evolve and thrive on AWS as they support their customers.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom